A Modified Epirubicin and Oxaliplatin Plus Capecitabine (EOX) Regimen as a Second- Line Therapy in Patients with Advanced Gastric Cancer

por Bozkaya, Yakup, Özdemir, Nuriye Yıldırım, Yazıcı, Ozan, Demirci, Nebi Serkan, Kurtipek, Alican, Erdem, Gökmen Umut, Ergün, Yakup, Zengin, Nurullah
Publicado 2018

Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

por Demirci, Nebi Serkan, Çavdar, Eyyüp, Erdem, Gokmen Umut, Hatipoglu, Engin, Celik, Emir, Sezer, Sevilay, Yolcu, Ahmet, Dogan, Mutlu, Seber, Erdogan Selcuk
Publicado 2023

Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?

por Demirci, Nebi S., Dogan, Mutlu, Erdem, Gokmen U., Kacar, Sabite, Turhan, Turan, Kilickap, Saadettin, Cigirgan, Lutfi C., Kayacetin, Ertugrul, Bozkaya, Yakup, Zengin, Nurullah
Publicado 2017